Advanced search
1 file | 524.56 KB Add to list

A randomized trial on the effect of oral combined estradiol and drospirenone on glucose and insulin metabolism in healthy menopausal women with a normal oral glucose tolerance test

(2020) MATURITAS. 138. p.36-41
Author
Organization
Abstract
Background: Menopause is often associated with a central accumulation of body fat. This provokes insulin resistance. The resulting hyperinsulinemia may increase the risk of diabetes, cardiovascular disease and breast cancer. Long-term studies indicate that menopausal hormone therapy (MHT) reduces insulin resistance. To broaden knowledge of the mechanisms behind the influence of MHT on glucose homeostasis we focused on the direct short-term effects of MHT with oral combined estradiol and drospirenone on glucose and insulin metabolism in healthy postmenopausal women. Methods: This randomized, placebo-controlled study recruited 80 healthy postmenopausal women. Women were randomized to treatment with estradiol 1 mg continuously combined with drospirenone 2 mg or placebo for 6-8 weeks. All participants underwent an oral glucose tolerance test (OGTT) before and after the treatment period. Glucose, insulin, fructosamine and C-peptide levels were measured in serum before and 30, 60, 90, 120 and 150 min after a 75-gram oral glucose challenge. Results: After intervention, significantly higher glucose levels at 120 min (p < 0.024) and 150 min (p < 0.030) were observed in the MHT group compared with the placebo group. These glucose levels remained within the normal range. A significantly lower insulin peak serum level (p < 0.040) and a non-significantly smaller area under the curve (AUC) for insulin levels (p = 0.192) was observed in the MHT group at the end of the study period relative to baseline. No significant change in the insulin AUC in the placebo group was observed. There were no significant differences in fructosamine, HOMA-IR and C-peptide levels between the MHT group and the placebo group. Conclusion: This double-blind randomized study (EC/2008/694) indicates that treating healthy, postmenopausal women with 1 mg estradiol continuously combined with 2 mg drospirenone significantly decreases peak insulin levels and increases peak glucose levels during an OGTT compared to placebo. These glucose levels remained within the normal range.
Keywords
HORMONE-REPLACEMENT THERAPY, BINDING GLOBULIN, POSTMENOPAUSAL WOMEN, RISK, FAT, WEIGHT, Menopause, Insulin metabolism, Hormonal treatment

Downloads

  • (...).pdf
    • full text (Published version)
    • |
    • UGent only
    • |
    • PDF
    • |
    • 524.56 KB

Citation

Please use this url to cite or link to this publication:

MLA
Depypere, Herman, et al. “A Randomized Trial on the Effect of Oral Combined Estradiol and Drospirenone on Glucose and Insulin Metabolism in Healthy Menopausal Women with a Normal Oral Glucose Tolerance Test.” MATURITAS, vol. 138, 2020, pp. 36–41, doi:10.1016/j.maturitas.2020.04.009.
APA
Depypere, H., Dierickx, A., Van de Velde, F., Stanczyk, F., OTTOY, L., Delanghe, J., & Lapauw, B. (2020). A randomized trial on the effect of oral combined estradiol and drospirenone on glucose and insulin metabolism in healthy menopausal women with a normal oral glucose tolerance test. MATURITAS, 138, 36–41. https://doi.org/10.1016/j.maturitas.2020.04.009
Chicago author-date
Depypere, Herman, Anneloor Dierickx, Frederique Van de Velde, F. Stanczyk, LIESBETH OTTOY, Joris Delanghe, and Bruno Lapauw. 2020. “A Randomized Trial on the Effect of Oral Combined Estradiol and Drospirenone on Glucose and Insulin Metabolism in Healthy Menopausal Women with a Normal Oral Glucose Tolerance Test.” MATURITAS 138: 36–41. https://doi.org/10.1016/j.maturitas.2020.04.009.
Chicago author-date (all authors)
Depypere, Herman, Anneloor Dierickx, Frederique Van de Velde, F. Stanczyk, LIESBETH OTTOY, Joris Delanghe, and Bruno Lapauw. 2020. “A Randomized Trial on the Effect of Oral Combined Estradiol and Drospirenone on Glucose and Insulin Metabolism in Healthy Menopausal Women with a Normal Oral Glucose Tolerance Test.” MATURITAS 138: 36–41. doi:10.1016/j.maturitas.2020.04.009.
Vancouver
1.
Depypere H, Dierickx A, Van de Velde F, Stanczyk F, OTTOY L, Delanghe J, et al. A randomized trial on the effect of oral combined estradiol and drospirenone on glucose and insulin metabolism in healthy menopausal women with a normal oral glucose tolerance test. MATURITAS. 2020;138:36–41.
IEEE
[1]
H. Depypere et al., “A randomized trial on the effect of oral combined estradiol and drospirenone on glucose and insulin metabolism in healthy menopausal women with a normal oral glucose tolerance test,” MATURITAS, vol. 138, pp. 36–41, 2020.
@article{8694583,
  abstract     = {{Background: Menopause is often associated with a central accumulation of body fat. This provokes insulin resistance. The resulting hyperinsulinemia may increase the risk of diabetes, cardiovascular disease and breast cancer. Long-term studies indicate that menopausal hormone therapy (MHT) reduces insulin resistance. To broaden knowledge of the mechanisms behind the influence of MHT on glucose homeostasis we focused on the direct short-term effects of MHT with oral combined estradiol and drospirenone on glucose and insulin metabolism in healthy postmenopausal women.

Methods: This randomized, placebo-controlled study recruited 80 healthy postmenopausal women. Women were randomized to treatment with estradiol 1 mg continuously combined with drospirenone 2 mg or placebo for 6-8 weeks. All participants underwent an oral glucose tolerance test (OGTT) before and after the treatment period. Glucose, insulin, fructosamine and C-peptide levels were measured in serum before and 30, 60, 90, 120 and 150 min after a 75-gram oral glucose challenge.

Results: After intervention, significantly higher glucose levels at 120 min (p < 0.024) and 150 min (p < 0.030) were observed in the MHT group compared with the placebo group. These glucose levels remained within the normal range.

A significantly lower insulin peak serum level (p < 0.040) and a non-significantly smaller area under the curve (AUC) for insulin levels (p = 0.192) was observed in the MHT group at the end of the study period relative to baseline. No significant change in the insulin AUC in the placebo group was observed. There were no significant differences in fructosamine, HOMA-IR and C-peptide levels between the MHT group and the placebo group.

Conclusion: This double-blind randomized study (EC/2008/694) indicates that treating healthy, postmenopausal women with 1 mg estradiol continuously combined with 2 mg drospirenone significantly decreases peak insulin levels and increases peak glucose levels during an OGTT compared to placebo. These glucose levels remained within the normal range.}},
  author       = {{Depypere, Herman and Dierickx, Anneloor and Van de Velde, Frederique and Stanczyk, F. and OTTOY, LIESBETH and Delanghe, Joris and Lapauw, Bruno}},
  issn         = {{0378-5122}},
  journal      = {{MATURITAS}},
  keywords     = {{HORMONE-REPLACEMENT THERAPY,BINDING GLOBULIN,POSTMENOPAUSAL WOMEN,RISK,FAT,WEIGHT,Menopause,Insulin metabolism,Hormonal treatment}},
  language     = {{eng}},
  location     = {{Amsterdam, Netherlands}},
  pages        = {{36--41}},
  title        = {{A randomized trial on the effect of oral combined estradiol and drospirenone on glucose and insulin metabolism in healthy menopausal women with a normal oral glucose tolerance test}},
  url          = {{http://dx.doi.org/10.1016/j.maturitas.2020.04.009}},
  volume       = {{138}},
  year         = {{2020}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: